NCT05299398

Prevention of Postpartum Depression: A Pilot Placebo-controlled Trial of Trazodone

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Verinder Sharma · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

Postpartum depression is a serious illness that affects approximately 17% of women who have recently given birth. Untreated depression appears to have negative effects for both the mother and her baby. Postpartum depression is quite common among women with a history of depression. Sleeplessness is a common concern during pregnancy and after delivery, and it can also trigger depression in women with a history of depression. Antidepressants are the most commonly recommended drugs for prevention of postpartum depression; however, there is limited research to understand the effectiveness of the medications in preventing postpartum depression. Trazodone is a weak antidepressant, but it is commonly prescribed for sleeplessness due to physical or psychiatric disorders. We are planning a study to find out whether trazodone in a low dose is more effective than a sugar pill in preventing postpartum depression among women with histories of depression. We expect the results of our study will make it easier for healthcare providers to select the right medication for women who are at risk of developing depression after delivery and thus improve the mental health of mothers and well-being of their babies.

Conditions

• Postpartum Depression

Interventions

Type	Name	Description
DRUG	Trazodone	Trazodone capsule once daily
DRUG	Placebo	Placebo capsule once daily

Timeline

• Start date: 2025-04-17
• Primary completion: 2025-08-31
• Completion: 2025-08-31
• First posted: 2022-03-29
• Last updated: 2025-04-04

Locations

1 site across 1 country: Canada